PE20191349A1 - Inhibidores de mnk sustituidos con piperidina y metodos relacionados con los mismos - Google Patents
Inhibidores de mnk sustituidos con piperidina y metodos relacionados con los mismosInfo
- Publication number
- PE20191349A1 PE20191349A1 PE2019001676A PE2019001676A PE20191349A1 PE 20191349 A1 PE20191349 A1 PE 20191349A1 PE 2019001676 A PE2019001676 A PE 2019001676A PE 2019001676 A PE2019001676 A PE 2019001676A PE 20191349 A1 PE20191349 A1 PE 20191349A1
- Authority
- PE
- Peru
- Prior art keywords
- piperidine
- amino
- alkyl
- related methods
- compounds
- Prior art date
Links
- NQRYJNQNLNOLGT-UHFFFAOYSA-N Piperidine Chemical group C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 title 2
- 239000003112 inhibitor Substances 0.000 title 1
- 150000001875 compounds Chemical class 0.000 abstract 3
- -1 AMINO Chemical class 0.000 abstract 2
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 108091000080 Phosphotransferase Proteins 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 229910052736 halogen Inorganic materials 0.000 abstract 1
- 150000002367 halogens Chemical class 0.000 abstract 1
- 229940043355 kinase inhibitor Drugs 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 102000020233 phosphotransferase Human genes 0.000 abstract 1
- 239000003757 phosphotransferase inhibitor Substances 0.000 abstract 1
- XVIAPHVAGFEFFN-UHFFFAOYSA-N pyrimidine-5-carbonitrile Chemical compound N#CC1=CN=CN=C1 XVIAPHVAGFEFFN-UHFFFAOYSA-N 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
- C07D471/20—Spiro-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Plural Heterocyclic Compounds (AREA)
- Hydrogenated Pyridines (AREA)
Abstract
SE REFIERE A COMPUESTOS SUSTITUIDOS CON PIPERIDINA DE FORMULA (I) DONDE X1 ES CH2 Y X2 ES NR2 O X1 ES NR2 Y X2 ES CH2; R1 ES H, ALQUILO(C1-C4), HALOGENO O CN; R2 ES H, ALQUILO(C1-C8) O HALOALQUILO(C1-C8); R3 ES ALQUILO(C1-C8), O R2 Y UN ADYACENTE R3, O R3 Y UN ADYACENTE R3, JUNTO CON LOS ATOMOS DEL ANILLO AL QUE ESTAN UNIDOS, FORMAN UN ANILLO DE CICLOALQUILO O HETEROCICLO FUSIONADO DE CINCO O SEIS MIEMBROS; n ES DE 0 A 4. SON COMPUESTOS PREFERIDOS: (R)-6-((6-AMINO-5-METILPIRIMIDIN-4-IL)AMINO)-1',8-DIMETIL-2H-ESPIRO[IMIDAZO[1,5-a]PIRIDINA-3,3'-PIPERIDINA]-1,5-DIONA; (R)-4-AMINO-6-((1',8-DIMETIL-1,5-DIOXO-1,5-DIHIDRO-2H-ESPIRO[IMIDAZO[1,5-a]PIRIDINA-3,3'-PIPERIDIN]-6-IL)AMINO)PIRIMIDINA-5-CARBONITRILO; ENTRE OTROS. TAMBIEN SE REFIERE A UNA COMPOSICION FARMACEUTICA. DICHOS COMPUESTOS SON INHIBIDORES DE QUINASA QUE INTERACTUAN CON MAP QUINASA (MnK) SIENDO UTILES EN EL TRATAMIENTO DE CANCER
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762458671P | 2017-02-14 | 2017-02-14 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PE20191349A1 true PE20191349A1 (es) | 2019-09-30 |
Family
ID=63106539
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PE2019001676A PE20191349A1 (es) | 2017-02-14 | 2018-02-13 | Inhibidores de mnk sustituidos con piperidina y metodos relacionados con los mismos |
Country Status (22)
| Country | Link |
|---|---|
| US (3) | US20180228803A1 (es) |
| EP (1) | EP3582776B1 (es) |
| JP (2) | JP2020507588A (es) |
| KR (1) | KR20190117013A (es) |
| CN (1) | CN110719781A (es) |
| AU (2) | AU2018220840A1 (es) |
| BR (1) | BR112019016707A2 (es) |
| CA (1) | CA3053493A1 (es) |
| CL (1) | CL2019002297A1 (es) |
| CO (1) | CO2019009423A2 (es) |
| DK (1) | DK3582776T3 (es) |
| EA (1) | EA201991894A1 (es) |
| ES (1) | ES2969988T3 (es) |
| FI (1) | FI3582776T3 (es) |
| IL (1) | IL268619B (es) |
| MX (1) | MX394700B (es) |
| MY (1) | MY199730A (es) |
| PE (1) | PE20191349A1 (es) |
| PH (1) | PH12019550140A1 (es) |
| SG (1) | SG11201907356SA (es) |
| TW (1) | TWI762579B (es) |
| WO (1) | WO2018152117A1 (es) |
Families Citing this family (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DK3582776T3 (da) | 2017-02-14 | 2024-01-08 | Effector Therapeutics Inc | Piperidinsubstituerede mnk-hæmmere og dertil relaterede fremgangsmåder |
| CN113286592A (zh) | 2018-10-24 | 2021-08-20 | 效应治疗股份有限公司 | Mnk抑制剂的结晶形式 |
| CN111484494B (zh) | 2019-01-29 | 2022-09-13 | 诺沃斯达药业(上海)有限公司 | 抑制mnk1和mnk2的多环化合物 |
| HRP20241540T1 (hr) | 2019-11-18 | 2025-01-03 | Jumbo Drug Bank Co., Ltd. | Pirolotriazinski spojevi koji djeluju kao inhibitor mnk |
| WO2022038563A1 (en) * | 2020-08-20 | 2022-02-24 | Hepagene Therapeutics (HK) Limited | Mnk inhibitors |
| JP7638031B2 (ja) * | 2021-05-08 | 2025-03-03 | 成都嘉葆薬銀医薬科技有限公司 | ピロロトリアジン系化合物の塩形、その結晶形及びその製造方法 |
| CN114736205B (zh) * | 2022-03-31 | 2023-03-03 | 武汉九州钰民医药科技有限公司 | 化合物Tomivosertib的制备方法 |
| CN114853756B (zh) * | 2022-03-31 | 2023-03-28 | 武汉九州钰民医药科技有限公司 | 化合物Tomivosertib的制备工艺 |
| WO2024017229A1 (zh) * | 2022-07-19 | 2024-01-25 | 成都嘉葆药银医药科技有限公司 | 一种吡咯并三嗪类化合物在制备抗肿瘤药物中的应用 |
| CN116425750A (zh) * | 2023-02-10 | 2023-07-14 | 诺沃斯达药业(上海)有限公司 | 一种mnk抑制剂化合物的盐、晶体及其制备方法 |
| TW202508595A (zh) | 2023-05-04 | 2025-03-01 | 美商銳新醫藥公司 | 用於ｒａｓ相關疾病或病症之組合療法 |
| WO2025034702A1 (en) | 2023-08-07 | 2025-02-13 | Revolution Medicines, Inc. | Rmc-6291 for use in the treatment of ras protein-related disease or disorder |
| TW202525802A (zh) * | 2023-09-02 | 2025-07-01 | 美商必治妥美雅史谷比公司 | 經取代之苯基氧代㗁唑基哌啶二酮化合物 |
| US20250154171A1 (en) | 2023-10-12 | 2025-05-15 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2025137653A1 (en) * | 2023-12-20 | 2025-06-26 | Mellicell, Inc. | Methods and compositions of polycyclic and a dual acting nitroxide compounds for treatment of fat cell associated diseases |
| WO2025171296A1 (en) | 2024-02-09 | 2025-08-14 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2025240847A1 (en) | 2024-05-17 | 2025-11-20 | Revolution Medicines, Inc. | Ras inhibitors |
Family Cites Families (54)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5491144A (en) | 1991-05-30 | 1996-02-13 | Ciba-Geigy Corporation | Substituted diaminophthalimides and analogues |
| DE60219788T2 (de) | 2001-06-05 | 2008-01-17 | Lilly Icos Llc, Wilmington | Tetrazyklische verbindungen als pde5-inhibitoren |
| ES2359233T3 (es) | 2001-10-29 | 2011-05-19 | Boehringer Ingelheim International Gmbh | Proteínas homólogas de la quinasa mnk implicadas en la regulación de la homeostasis energética y en el metabolismo organular. |
| US20050012622A1 (en) | 2003-05-19 | 2005-01-20 | Sutton William R. | Monitoring and control of sleep cycles |
| TWI301760B (en) | 2004-02-27 | 2008-10-11 | Merz Pharma Gmbh & Co Kgaa | Tetrahydroquinolinones and their use as antagonists of metabotropic glutamate receptors |
| US7488745B2 (en) | 2004-07-16 | 2009-02-10 | Schering Corporation | Compounds for the treatment of inflammatory disorders |
| TW200613272A (en) | 2004-08-13 | 2006-05-01 | Astrazeneca Ab | Isoindolone compounds and their use as metabotropic glutamate receptor potentiators |
| US20060281670A1 (en) | 2005-06-10 | 2006-12-14 | Wisconsin Alumni Research Foundation (Warf) | Compositions and methods for modulating angiogenesis |
| JP2009509921A (ja) | 2005-08-12 | 2009-03-12 | アストラゼネカ アクチボラグ | 置換イソインドロン類及び代謝調節型グルタミン酸受容体増強剤としてのその使用 |
| CA2654358A1 (en) | 2006-06-22 | 2007-12-27 | Biovitrum Ab (Publ) | Pyridine and pyrazine derivatives as mnk kinase inhibitors |
| EP1889847A1 (en) | 2006-07-10 | 2008-02-20 | DeveloGen Aktiengesellschaft | Pyrrolopyrimidines for pharmaceutical compositions |
| DK2134689T3 (da) | 2007-03-16 | 2014-06-30 | Scripps Research Inst | Inhibitorer af fokal adhæsionskinase |
| GB0706072D0 (en) | 2007-03-28 | 2007-05-09 | Sterix Ltd | Compound |
| CA2706203A1 (en) | 2007-11-22 | 2009-05-28 | Boehringer Ingelheim International Gmbh | Use of mnk inhibitors for the treatment of alzheimer's disease |
| JP2009173629A (ja) | 2007-12-21 | 2009-08-06 | Banyu Pharmaceut Co Ltd | Ｒｓｋ１阻害作用を有する新規スピロインダン誘導体 |
| WO2009112445A1 (en) | 2008-03-10 | 2009-09-17 | Novartis Ag | Method of increasing cellular phosphatidyl choline by dgat1 inhibition |
| JP5675614B2 (ja) | 2008-08-26 | 2015-02-25 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | 医薬組成物用のチエノピリミジン |
| EP2355819A2 (en) | 2008-11-12 | 2011-08-17 | Novartis Forschungsstiftung, Zweigniederlassung Friedrich Miescher Institute For Biomedical Research | Treating cancer by modulating a mnk |
| US8637525B2 (en) | 2009-07-31 | 2014-01-28 | Bristol-Myers Squibb Company | Compounds for the reduction of beta-amyloid production |
| TWI468402B (zh) | 2009-07-31 | 2015-01-11 | 必治妥美雅史谷比公司 | 降低β－類澱粉生成之化合物 |
| TWI393716B (zh) | 2009-08-04 | 2013-04-21 | Merck Sharp & Dohme | 作為ｉｘａ因子抑制劑之雜環化合物 |
| US8604217B2 (en) | 2009-11-12 | 2013-12-10 | Selvita S.A. | Compound, a process for its preparation, a pharmaceutical composition, use of a compound, a method for modulating or regulating serine/threonine kinases and a serine/threonine kinases modulating agent |
| WO2011106168A1 (en) | 2010-02-24 | 2011-09-01 | Dcam Pharma Inc | Purine compounds for treating autoimmune and demyelinating diseases |
| PE20140165A1 (es) | 2010-10-01 | 2014-02-26 | Bayer Ip Gmbh | Combinaciones que contienen n-(2-arilamino)arilsulfonamida |
| WO2012075140A1 (en) | 2010-11-30 | 2012-06-07 | Pharmasset, Inc. | Compounds |
| US9938269B2 (en) | 2011-06-30 | 2018-04-10 | Abbvie Inc. | Inhibitor compounds of phosphodiesterase type 10A |
| WO2013043192A1 (en) | 2011-09-23 | 2013-03-28 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Galactokinase inhibitors for the treatment and prevention of associated diseases and disorders |
| EP2797927B1 (en) | 2011-12-30 | 2019-09-25 | Hanmi Pharm. Co., Ltd. | THIENO[3,2-d]PYRIMIDINE DERIVATIVES HAVING INHIBITORY ACTIVITY FOR PROTEIN KINASES |
| CA2868966C (en) | 2012-03-29 | 2021-01-26 | Francis Xavier Tavares | Lactam kinase inhibitors |
| GB201205669D0 (en) | 2012-03-30 | 2012-05-16 | Agency Science Tech & Res | Bicyclic heterocyclic derivatives as mnk2 and mnk2 modulators and uses thereof |
| US10280168B2 (en) | 2012-03-30 | 2019-05-07 | Agency For Science, Technology And Research | Bicyclic heteroaryl derivatives as MNK1 and MNK2 modulators and uses thereof |
| WO2013151975A1 (en) | 2012-04-02 | 2013-10-10 | Northeastern University | Compositions and methods for the inhibition of methyltransferases |
| WO2013174743A1 (en) | 2012-05-21 | 2013-11-28 | Bayer Pharma Aktiengesellschaft | Substituted pyrrolopyrimidines |
| TW201412740A (zh) | 2012-09-20 | 2014-04-01 | Bayer Pharma AG | 經取代之吡咯并嘧啶胺基苯并噻唑酮 |
| JP6306035B2 (ja) | 2012-11-09 | 2018-04-04 | エヴォテック・インターナショナル・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツングＥｖｏｔｅｃ Ｉｎｔｅｒｎａｔｉｏｎａｌ ＧｍｂＨ | 医薬組成物のためのスルホキシミン置換キナゾリン |
| GB2508652A (en) | 2012-12-07 | 2014-06-11 | Agency Science Tech & Res | Heterocyclic piperazine derivatives |
| WO2014099941A1 (en) | 2012-12-19 | 2014-06-26 | Idenix Pharmaceuticals, Inc. | 4'-fluoro nucleosides for the treatment of hcv |
| EP2958920A1 (en) | 2013-02-20 | 2015-12-30 | Bayer Pharma Aktiengesellschaft | Substituted-imidazo[1,2-b]pyridazines as mknk1 inhibitors |
| TW201605867A (zh) | 2013-11-20 | 2016-02-16 | 拜耳製藥公司 | 噻吩并嘧啶 |
| TWI713455B (zh) | 2014-06-25 | 2020-12-21 | 美商伊凡克特治療公司 | ＭｎＫ抑制劑及其相關方法 |
| EP3233866B1 (en) | 2014-12-19 | 2021-04-21 | Bayer Pharma Aktiengesellschaft | Pyrazolopyridinamines as mknk1 and mknk2 inhibitors |
| WO2016172010A1 (en) * | 2015-04-20 | 2016-10-27 | Effector Therapeutics, Inc. | Inhibitors of immune checkpoint modulators for use in treating cancer and infections |
| EA201891049A1 (ru) | 2015-10-29 | 2018-10-31 | Эффектор Терапьютикс, Инк. | Изоиндолиновые, азаизоиндолиновые, дигидроинденоновые и дигидроазаинденоновые ингибиторы mnk1 и mnk2 |
| WO2017075412A1 (en) | 2015-10-29 | 2017-05-04 | Effector Therapeutics, Inc. | Pyrrolo-, pyrazolo-, imidazo-pyrimidine and pyridine compounds that inhibit mnk1 and mnk2 |
| GB201520500D0 (en) | 2015-11-20 | 2016-01-06 | Medical Res Council Technology | Compounds |
| US10000487B2 (en) | 2015-11-20 | 2018-06-19 | Effector Therapeutics, Inc. | Heterocyclic compounds that inhibit the kinase activity of Mnk useful for treating various cancers |
| GB201520499D0 (en) | 2015-11-20 | 2016-01-06 | Medical Res Council Technology | Compounds |
| US20170191136A1 (en) | 2015-12-31 | 2017-07-06 | Effector Therapeutics, Inc. | Mnk biomarkers and uses thereof |
| CN110088099B (zh) * | 2016-12-19 | 2023-01-31 | Epizyme股份有限公司 | 作为ehmt2抑制剂的胺取代的杂环化合物及其使用方法 |
| DK3582776T3 (da) | 2017-02-14 | 2024-01-08 | Effector Therapeutics Inc | Piperidinsubstituerede mnk-hæmmere og dertil relaterede fremgangsmåder |
| WO2018218038A1 (en) | 2017-05-24 | 2018-11-29 | Effector Therapeutics, Inc. | Methods and compositions for cellular immunotherapy |
| AU2018368731A1 (en) | 2017-11-16 | 2020-05-14 | Novartis Ag | Combination therapies |
| US20200297696A1 (en) | 2017-11-21 | 2020-09-24 | Saint Louis University | P38 inhibitors for the treatment of fshd |
| CN113286592A (zh) | 2018-10-24 | 2021-08-20 | 效应治疗股份有限公司 | Mnk抑制剂的结晶形式 |
-
2018
- 2018-02-13 DK DK18754330.1T patent/DK3582776T3/da active
- 2018-02-13 AU AU2018220840A patent/AU2018220840A1/en not_active Abandoned
- 2018-02-13 WO PCT/US2018/018022 patent/WO2018152117A1/en not_active Ceased
- 2018-02-13 BR BR112019016707A patent/BR112019016707A2/pt not_active Application Discontinuation
- 2018-02-13 EP EP18754330.1A patent/EP3582776B1/en active Active
- 2018-02-13 MX MX2019009653A patent/MX394700B/es unknown
- 2018-02-13 TW TW107105327A patent/TWI762579B/zh active
- 2018-02-13 FI FIEP18754330.1T patent/FI3582776T3/fi active
- 2018-02-13 ES ES18754330T patent/ES2969988T3/es active Active
- 2018-02-13 PE PE2019001676A patent/PE20191349A1/es unknown
- 2018-02-13 CN CN201880011685.6A patent/CN110719781A/zh active Pending
- 2018-02-13 CA CA3053493A patent/CA3053493A1/en active Pending
- 2018-02-13 JP JP2019543809A patent/JP2020507588A/ja active Pending
- 2018-02-13 MY MYPI2019004638A patent/MY199730A/en unknown
- 2018-02-13 SG SG11201907356SA patent/SG11201907356SA/en unknown
- 2018-02-13 EA EA201991894A patent/EA201991894A1/ru unknown
- 2018-02-13 KR KR1020197026790A patent/KR20190117013A/ko not_active Ceased
- 2018-02-13 US US15/895,523 patent/US20180228803A1/en not_active Abandoned
- 2018-12-27 US US16/233,507 patent/US11083727B2/en not_active Expired - Fee Related
-
2019
- 2019-08-09 PH PH12019550140A patent/PH12019550140A1/en unknown
- 2019-08-11 IL IL268619A patent/IL268619B/en unknown
- 2019-08-13 CL CL2019002297A patent/CL2019002297A1/es unknown
- 2019-08-29 CO CONC2019/0009423A patent/CO2019009423A2/es unknown
-
2021
- 2021-08-06 US US17/396,187 patent/US11878015B2/en active Active
-
2022
- 2022-04-29 AU AU2022202864A patent/AU2022202864B2/en not_active Ceased
- 2022-09-29 JP JP2022156442A patent/JP2022185050A/ja active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PE20191349A1 (es) | Inhibidores de mnk sustituidos con piperidina y metodos relacionados con los mismos | |
| PE20170321A1 (es) | Inhibidores de cinasa de interaccion con proteina cinasa activada por mitogeno (mnk) y metodos relacionados con los mismos | |
| PE20120224A1 (es) | Derivados de 1h-imidazo-[4,5-c]-quinolinona | |
| DOP2018000187A (es) | Derivados de pirazolo[1,5-a]pirazin-4-ilo | |
| AR063099A1 (es) | Compuestos y composiciones como inhibidores de la proteina quinasa | |
| PE20190475A1 (es) | Inhibidores de cdk2/4/6 | |
| PE20130306A1 (es) | Morfolinopirimidinas y su uso en terapia | |
| PE20140250A1 (es) | Derivados de piperidina puenteada | |
| AR107127A1 (es) | Indazoles sustituidos, procedimientos para su preparación, preparaciones farmacéuticas que los contienen, así como su uso para la preparación de medicamentos | |
| AR081252A1 (es) | Compuestos para el tratamiento del sindrome metabolico | |
| AR074435A1 (es) | Derivados de 1,3-benzotiazol, medicamentos que los contienen y uso de los mismos en el tratamiento del cancer. | |
| AR106040A1 (es) | Moduladores de la proteína core de la hepatitis b | |
| PE20150218A1 (es) | Nuevos derivados fosfatos, su procedimiento de preparacion y las composiciones farmaceuticas que los contienen | |
| AR080785A1 (es) | Derivados de imidazo[1,2-a]pirimidina ,proceso para prepararlos e intermediarios de dicha sintesis, composiciones farmaceuticas que los contienen y uso de los mismos en el tratamiento de patologias del sistema nervioso central,tales como esquizofrenia y parkinson, entre otros. | |
| PE20190811A1 (es) | Derivados de pirazolopirimidinas como inhibidor de quinasa | |
| PE20070752A1 (es) | Triazolopiridazinas como moduladores de quinasa | |
| AR036716A1 (es) | Un compuesto derivado de bencimidazolidinona, metodos que lo utilizan, una composicion farmaceutica que lo comprende y uso de dicho compuesto o composicion | |
| PE20081844A1 (es) | DERIVADOS DE INDOL-3-IL-CARBONIL-AZASPIROPIPERIDINA COMO ANTAGONISTAS DEL RECEPTOR V1a | |
| AR037731A1 (es) | Uso de ureas de benzotiazoles | |
| PE20060185A1 (es) | ANTAGONISTA DEL RECEPTOR A2A DE LA ADENOSINA CON ESTRUCTURA DE PIRAZOLO--[4,3-e]-1,2,4-TRIAZOLO-[1,5-c]-PIRIMIDINA | |
| PE20081152A1 (es) | Azaciclilaminas n-sustituidas como antagonistas de histamina-3 | |
| AR040047A1 (es) | 1-(aminoalquil)-3-sulfonilazaindoles como ligandos de la 5-hidroxitriptamina-6 | |
| AR078841A1 (es) | Derivados de imidazo(1,2-b) piridazina y su uso como inhibidores de pde10 | |
| AR043181A1 (es) | Heterociclil-3-sulfonilindazoles como ligandos de 5-hidroxiptamina-6 | |
| AR037680A1 (es) | Antagonistas del receptor de adenosina a2a de 5-amino-pirazolo-[4,3-e]-1,2,4-triazolo[1,5-c]-pirimidinas sustituidas, composiciones farmaceuticas que los comprenden, el uso de dichos compuestos, solos o en combinacion para la elaboracion de un medicamento utiles para el tratamiento de enfermedades d |